BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:A2B530 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of A2B530\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05736731-2310@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:A2B530: Phase 1/2 readout est. (NCT05736731)
DESCRIPTION:A2B530\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B530\, a Logic-gated CAR T\, in
  Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Ex
 pression\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/a2b530#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05736731
URL:https://assetmemo.bio/drug/a2b530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
